Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De Sells 79,712 Shares

Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Backer Marianne De sold 79,712 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the sale, the chief executive officer now directly owns 769,505 shares of the company’s stock, valued at approximately $4,578,554.75. This represents a 9.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Vir Biotechnology Trading Down 6.4 %

Shares of VIR opened at $5.58 on Friday. Vir Biotechnology, Inc. has a 12-month low of $5.49 and a 12-month high of $14.45. The company has a market capitalization of $765.26 million, a PE ratio of -1.42 and a beta of 1.14. The business’s 50 day moving average is $8.36 and its 200 day moving average is $8.29.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. Equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current year.

Analysts Set New Price Targets

VIR has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a research note on Thursday, February 27th. Barclays upped their price target on Vir Biotechnology from $26.00 to $31.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Friday, February 28th. Leerink Partners increased their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, January 13th. Finally, Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $10.00 to $20.00 in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $35.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vir Biotechnology in the fourth quarter worth about $42,000. SBI Securities Co. Ltd. bought a new position in Vir Biotechnology during the fourth quarter valued at approximately $60,000. PNC Financial Services Group Inc. grew its holdings in Vir Biotechnology by 31.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after buying an additional 1,999 shares in the last quarter. KBC Group NV increased its stake in Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after acquiring an additional 5,177 shares during the last quarter. Finally, CIBC Asset Management Inc purchased a new stake in shares of Vir Biotechnology during the 4th quarter worth approximately $74,000. Institutional investors own 65.32% of the company’s stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).